{"nctId":"NCT03427125","briefTitle":"A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis","startDateStruct":{"date":"2018-01-08","type":"ACTUAL"},"conditions":["Hyperphosphatemia"],"count":1559,"armGroups":[{"label":"Tenapanor 10 mg, 20 mg, 30 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Tenapanor"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Sevelamer Carbonate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sevelamer Carbonate"]}],"interventions":[{"name":"Tenapanor","otherNames":["RDX5791, AZD1722"]},{"name":"Placebo","otherNames":[]},{"name":"Sevelamer Carbonate","otherNames":["Renvela"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females must be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods\n* Males must agree to avoid fathering a child and agree to use an appropriate method of contraception\n* Chronic maintenance hemodialysis 3x a week for at least 3 months\n* Chronic maintenance peritoneal dialysis for a minimum of 6 months\n* Kt/V â‰¥ 1.2 at most recent measurement prior to screening\n* Prescribed and taking at least 3 doses of phosphate binder per day\n* Serum phosphorus levels should be between 4.0 and 8.0 mg/dL at screening\n* Unchanged dose of vitamin D or calcimimetics for the last 4 weeks prior to screening\n* For enrollment in the study after at least 2 weeks of wash-out, subjects must have serum phosphorus levels of at least 6.0 mg/dL but not more than 10.0 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value after 2 or 3 weeks wash-out of phosphate binders\n\nExclusion Criteria:\n\n* Severe hyperphosphatemia defined as serum phosphorus greater than 10.0 mg/dL on phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening visit\n* Serum/plasma parathyroid hormone \\>1200 pg/mL\n* Clinical signs of hypovolemia at enrollment\n* History of IBD or IBS-D\n* Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period\n* Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator\n* Life expectancy \\<6 months\n* Previous exposure to tenapanor","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population","description":"Patients with at least a 1.2 mg/dL decrease in serum phosphorus during the first 26 weeks of the study were defined as the responder population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.199"},{"groupId":"OG001","value":"1.80","spread":"0.196"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the ITT Population","description":"Placebo Adjusted Change in Serum Phosphorus from the beginning to the end of the Randomized Withdrawal Period in all patients","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.149"},{"groupId":"OG001","value":"0.88","spread":"0.150"}]}]}]},{"type":"SECONDARY","title":"Serum Phosphorus From Baseline","description":"Serum Phosphorus from baseline (post washout) to end of 26 week period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.44","spread":"1.439"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.88","spread":"1,455"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":419},"commonTop":["Diarrhea"]}}}